
Bayer AG arm Vividion Therapeutics doses first patient in Phase I study of Inhibitor for advanced solid tumors treatment
San Diego: Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS-driven cancers. Vividion is a clinical-stage …